Abelacimab (MAA868) is a fully humanIgG1monoclonal antibody that binds with high affinity to the catalytic structural domain ofFXIand locks it in the zymogen conformation, thereby preventing its activation by FXIIa orthrombin. Abelacimab can be used in thromboembolic disease studies^[1][2].

Abelacimab (MAA868) (0.0001-1 μM) 以浓度依赖的方式延长凝血时间并减少人血浆中的凝血酶数量^[1]。

Abelacimab (MAA868) (s.c., 3-30 mg/kg, on day 1, 85, 114) 在食蟹猴中表现出强烈和持续的抗凝血作用，显着延长 aPTT，且具有较好的安全性，未观察到显着的毒性发现或出血迹象^[1]。
Abelacimab (MAA868) (i.v., 0.6 mg/kg) 在氯化铁诱导的血栓形成 FXI^-/-C57BL/6 小鼠模型中表现出良好的抗凝血活性，以防止颈动脉阻塞^[1]。

2098724-83-3

Please store the product under the recommended conditions in the Certificate of Analysis.